Ohmy-To The Moon - Tiger Brokers Online Investing Community

8
Comment
Favorite

joyciology
2022-03-04

Ohmy

Ocugen: FDA Declines EUA for Covid-19 Vaccine in Ages 2 to 18

Ocugen Inc. said Friday that the U.S. Food and Drug Administration has declined to issue an Emergenc

Ocugen: FDA Declines EUA for Covid-19 Vaccine in Ages 2 to 18

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

BabySim
·2022-03-04
Ok
Reply
Like
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9031056202,"tweetId":"9031056202","gmtCreate":1646397784008,"gmtModify":1676534125366,"author":{"id":3582108671334900,"idStr":"3582108671334900","authorId":3582108671334900,"authorIdStr":"3582108671334900","name":"joyciology","avatar":"https://static.tigerbbs.com/bd90c4b20dfdf9210ef5daec9af84af3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Ohmy</p></body></html>","htmlText":"<html><head></head><body><p>Ohmy</p></body></html>","text":"Ohmy","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9031056202","repostId":1100317858,"repostType":2,"repost":{"id":"1100317858","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1646397059,"share":"https://www.laohu8.com/m/news/1100317858?lang=&edition=full","pubTime":"2022-03-04 20:30","market":"us","language":"en","title":"Ocugen: FDA Declines EUA for Covid-19 Vaccine in Ages 2 to 18","url":"https://stock-news.laohu8.com/highlight/detail?id=1100317858","media":"Tiger Newspress","summary":"Ocugen Inc. said Friday that the U.S. Food and Drug Administration has declined to issue an Emergenc","content":"<html><head></head><body><p>Ocugen Inc. said Friday that the U.S. Food and Drug Administration has declined to issue an Emergency Use Authorization for Covaxin.</p><p>The biopharmaceutical company said its Covaxin vaccine&#39;s EUA was for active immunization to prevent Covid-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age.</p><p>Ocugen said it intends to continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin.</p><p>Ocugen shares were down 30%, to $2.3, in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/058278fe5f4ff9650db8611f698fda5b\" tg-width=\"840\" tg-height=\"619\" width=\"100%\" height=\"auto\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen: FDA Declines EUA for Covid-19 Vaccine in Ages 2 to 18</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen: FDA Declines EUA for Covid-19 Vaccine in Ages 2 to 18\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-03-04 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Ocugen Inc. said Friday that the U.S. Food and Drug Administration has declined to issue an Emergency Use Authorization for Covaxin.</p><p>The biopharmaceutical company said its Covaxin vaccine&#39;s EUA was for active immunization to prevent Covid-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age.</p><p>Ocugen said it intends to continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin.</p><p>Ocugen shares were down 30%, to $2.3, in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/058278fe5f4ff9650db8611f698fda5b\" tg-width=\"840\" tg-height=\"619\" width=\"100%\" height=\"auto\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100317858","content_text":"Ocugen Inc. said Friday that the U.S. Food and Drug Administration has declined to issue an Emergency Use Authorization for Covaxin.The biopharmaceutical company said its Covaxin vaccine's EUA was for active immunization to prevent Covid-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age.Ocugen said it intends to continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin.Ocugen shares were down 30%, to $2.3, in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":454,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":100719947,"commentId":"100719947","gmtCreate":1646402799498,"gmtModify":1663244634936,"authorId":3579673211261157,"author":{"id":3579673211261157,"idStr":"3579673211261157","authorId":3579673211261157,"name":"BabySim","avatar":"https://static.tigerbbs.com/5c6f0cd54fab9f24929e66e54e08e3aa","vip":1,"currentWearingBadge":{"badgeId":"4e86300037264823b9bb00ff44fc0f19-2","templateUuid":"4e86300037264823b9bb00ff44fc0f19","name":"Live trading challenger","description":"for 4 months ","bigImgUrl":"https://community-static.tradeup.com/news/555a9001c6de2ba066c0850c80b6475a","smallImgUrl":"https://community-static.tradeup.com/news/acd8d1536c6533b9c274771f100401c4","grayImgUrl":"https://community-static.tradeup.com/news/1c254e1fa3d75a472d0f55ebb1dd1ff4","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.03.03","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5600},"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9031056202,"objectIdStr":"9031056202","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}